日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir

SARS-CoV-2 Mpro 抑制剂 RAY1216 的临床前评估显示,与尼玛瑞韦相比,其药代动力学有所改善

Xiaoxin Chen #, Xiaodong Huang #, Qinhai Ma #, Petr Kuzmič #, Biao Zhou, Sai Zhang, Jizheng Chen, Jinxin Xu, Bin Liu, Haiming Jiang, Wenjie Zhang, Chunguang Yang, Shiguan Wu, Jianzhou Huang, Haijun Li, Chaofeng Long, Xin Zhao, Hongrui Xu, Yanan Sheng, Yaoting Guo, Chuanying Niu, Lu Xue, Yong Xu, Jin

Design, synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy

4-(3-氯-4-(3-环丙基硫脲基)-2-氟苯氧基)-7-甲氧基喹啉-6-甲酰胺 (WXFL-152) 的设计、合成和药理学评价:一种用于癌症治疗的新型三重血管激酶抑制剂

Yuqin Yao ,Zhuowei Liu ,Manyu Zhao ,Zhengxia Chen ,Peng Li ,Yang Zhang ,Yuxi Wang ,Chengjian Zhao ,Chaofeng Long ,Xiaoxin Chen ,Jinliang Yang

Chinese medicinal formula Fufang Xueshuantong capsule could inhibit the activity of angiotensin converting enzyme

中药复方血栓通胶囊对血管紧张素转换酶活性有抑制作用

Shujing Sheng, Yonggang Wang, Chaofeng Long, Weiwei Su, Xia Rong